Browse > Article
http://dx.doi.org/10.5483/BMBRep.2021.54.3.136

Combined application of rapamycin and atorvastatin improves lipid metabolism in apolipoprotein E-deficient mice with chronic kidney disease  

Song, Eun Ju (Immune and Vascular Cell Network Research Center, National Creative Initiatives, Department of Life Sciences, Ewha Womans University)
Ahn, Sanghyun (Department of Surgery, Seoul National University College of Medicine)
Min, Seung-Kee (Department of Surgery, Seoul National University College of Medicine)
Ha, Jongwon (Department of Surgery, Seoul National University College of Medicine)
Oh, Goo Taeg (Immune and Vascular Cell Network Research Center, National Creative Initiatives, Department of Life Sciences, Ewha Womans University)
Publication Information
BMB Reports / v.54, no.3, 2021 , pp. 170-175 More about this Journal
Abstract
Atherosclerosis arising from the pro-inflammatory conditions associated with chronic kidney disease (CKD) increases major cardiovascular morbidity and mortality. Rapamycin (RAPA) is known to inhibit atherosclerosis under CKD and non-CKD conditions, but it can cause dyslipidemia; thus, the co-application of lipid-lowering agents is recommended. Atorvastatin (ATV) has been widely used to reduce serum lipids levels, but its synergistic effect with RAPA in CKD remains unclear. Here, we analyzed the effect of their combined treatment on atherosclerosis stimulated by CKD in apolipoprotein E-deficient (ApoE-/-) mice. Oil Red O staining revealed that treatment with RAPA and RAPA＋ ATV, but not ATV alone, significantly decreased the atherosclerotic lesions in the aorta and aortic sinus, compared to those seen in the control (CKD) group. The co-administration of RAPA and ATV improved the serum lipid profile and raised the expression levels of proteins involved in reverse cholesterol transport (LXRα, CYP7A1, ABCG1, PPARγ, ApoA1) in the liver. The CKD group showed increased levels of various genes encoding atherosclerosispromoting cytokines in the spleen (Tnf-α, Il-6 and Il-1β) and aorta (Tnf-α and Il-4), and these increases were attenuated by RAPA treatment. ATV and RAPA＋ATV decreased the levels of Tnf-α and Il-1β in the spleen, but not in the aorta. Together, these results indicate that, in CKD-induced ApoE-/- mice, RAPA significantly reduces the development of atherosclerosis by regulating the expression of inflammatory cytokines and the co-application of ATV improves lipid metabolism.
Keywords
Atherosclerosis; Atorvastatin; Chronic kidney disease; Co-administration; Rapamycin;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kurdi A, De Meyer GR and Martinet W (2016) Potential therapeutic effects of mTOR inhibition in atherosclerosis. Br J Clin Pharmacol 82, 1267-1279   DOI
2 Ai D, Jiang H, Westerterp M et al (2014) Disruption of mammalian target of rapamycin complex 1 in macrophages decreases chemokine gene expression and atherosclerosis. Circ Res 114, 1576-1584   DOI
3 Hoogeveen RC, Ballantyne CM, Pownall HJ et al (2001) Effect of sirolimus on the metabolism of ApoB100-containing lipoproteins in renal transplant patients. Transplantation 72, 1244-1250   DOI
4 Pallet N and Legendre C (2012) Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf 12, 177-186   DOI
5 Kurdi A, Martinet W and De Meyer GRY (2018) mTOR Inhibition and Cardiovascular Diseases: Dyslipidemia and Atherosclerosis. Transplantation 102, S44-S46
6 Zhang X, Tian F, Kawai H et al (2012) Anti-inflammatory effect of amlodipine plus atorvastatin treatment on carotid atherosclerosis in zucker metabolic syndrome rats. Transl Stroke Res 3, 435-441   DOI
7 Liu D, Cui W, Liu B et al (2014) Atorvastatin protects vascular smooth muscle cells from TGF-β1-stimulated calcification by inducing autophagy via suppression of the β-catenin pathway. Cell Physiol Biochem 33, 129-141   DOI
8 London GM and Drueke TB (1997) Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 51, 1678-1695   DOI
9 Zoccali C and London G (2015) Con: vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease. Nephrol Dial Transplant 30, 352-357   DOI
10 Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A and Reed DP (2009) Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis 53, 741-750   DOI
11 Manni G, Gargaro M, Turco A et al (2018) Statins regulates inflammatory macrophage phenotype through the activation of AhR. J Immunol 200 (1 Supplement), 167.19
12 Yang HC, Zuo Y and Fogo AB (2010) Models of chronic kidney disease. Drug Discov Today Dis Models 7, 13-19   DOI
13 Mikolasevic I, Zutelija M, Mavrinac V and Orlic L (2017) Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis 10, 35-45   DOI
14 Massy ZA, Ivanovski O, Nguyen-Khoa T et al (2005) Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 16, 109-116   DOI
15 Gagnon RF and Gallimore B (1988) Characterization of a mouse model of chronic uremia. Urol Res 16, 119-126   DOI
16 Annema W and Tietge UJ (2012) Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. Nutr Metab (Lond) 9, 25   DOI
17 Apostolov EO, Ray D, Savenka AV, Shah SV and Basnakian AG (2010) Chronic uremia stimulates LDL cabamylation and atherosclerosis. J Am Soc Nephrol 21, 1852-1857   DOI
18 Houd VP, Brule S, Festuccia WT et al (2010) Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and imparing lipid deposition in adipose tissue. Diabetes 59, 1338-1348   DOI
19 Simha V, Qin S, Shah P et al (2017) Sirolimus therapy is associated with elevation in circulating PCSK9 levels in cardiac transplant patients. J Cardiovasc Trans Res 10, 9-15   DOI
20 Eid W, Dauner K, Courtney KC et al (2017) mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosome in mammalian cells. Proc Natl Acad Sci U S A 114, 7999-8004   DOI
21 Gupta S, Pandak WM and Hylemon PB (2002) LXRα is the dominant regulator of CYP7A1 transcription. Biochem Biophys Res Commun 293, 338-343   DOI
22 Haas ME, Levenson AE, Sun X et al (2016) The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation 134, 61-72   DOI
23 Peng N, Meng N, Wang S et al (2014) An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E-/- mice. Sci Rep 4, 5519   DOI
24 Martinet W, De Loof H and De Meyer GRY (2014) mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. Atherosclerosis 233, 601-607   DOI
25 Calkin AC and Tontonoz P (2010) Liver X recptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol 30, 1513-1518   DOI
26 Chisholm JW, Hong J, Mills SA and Lawn RM (2003) The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res 44, 2039-2048   DOI
27 Schiffrin EL, Lipman ML and Mann JF (2007) Chronic Kidney Disease. Circulation 116, 85-97   DOI
28 Soltani A, Bahreyni A, Boroumand N et al (2018) Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives. J Cell Physiol 233, 4783-4790   DOI
29 Kennedy MA, Barrera GC, Nakamura K et al (2005) ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metabolism 1, 121-131   DOI
30 Park J, Jeong S, Yu J, Kim G, Jeong LS and Oh GT (2018) LJ-1888, a selective antagonist for the A3 adenosine receptor, ameliorates the development of atherosclerosis and hypercholesterolemia in apolipoprotein E knock-out mice. BMB Rep 51, 520-525   DOI
31 Finch JL, Lee DH, Liapis H et al (2013) Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification. Kidney Int 84, 1145-1153   DOI
32 Stenvinkel P, Ketteler M, Johnson RJ et al (2005) IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. Kidney Int 67, 1216-1233   DOI
33 Zhao X, Liu Y, Zhong Y et al (2015) Atorvastatin Improves Inflammatory Response in Atherosclerosis by Upregulating the Expression of GARP. Mediators Inflamm 2015, 841472   DOI
34 Li H, Tao HR, Hu T et al (2010) Atorvastatin reduces calcification in rat arteries and vascular smooth muscle cells. Basic Clin Pharmacol Toxicol 107, 798-802   DOI
35 Himmelfarb J, Stenvinkel P, Ikizler TA and Hakim RM (2002) The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62, 1524-1538   DOI
36 Ketteler M, Schlieper G and Floege J (2006) Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 47, 1027-1034   DOI
37 Carrero JJ, Yilmaz MI, Lindholm B and Stenvinkel P (2008) Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif 26, 291-299   DOI
38 Tbahriti HF, Meknassi D, Moussaoui R et al (2013) Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines. World J Nephrol 2, 31-37   DOI
39 Gistera A and Hansson GK (2017) The immunology of atherosclerosis. Nat Rev Nephrol 13, 368-380   DOI
40 Zewinger S, Kleber ME, Rohrer L et al (2017) Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease. Eur Heart J 38, 1597-1607   DOI